GPTHEALTH

GPT Healthcare share price & financials

Price
₹152.54
Market cap
₹1.3k Cr
Sector
Healthcare
Calls analysed
7
Latest concall · Q1 FY27 · call held 04 Aug 2026

GPT Healthcare Limited Q1 FY27

Revenue from Operations ₹126.2 cr EBITDA ₹26.2 cr EBITDA Margin 20.4% PAT ₹12.7 cr +66%

What went well

  • Strong financial performance with total income up 18.2% and PAT up 66% YoY.
  • ARPOB improved to INR 42,350, driven by a favorable case mix and focus on high-end tertiary care.
  • Mature hospitals maintained healthy occupancy at 58.07%, with Salt Lake at 62% and Dumdum at 65%.

What to watch

  • Agartala hospital experienced a slight decrease in occupancy due to geopolitical reasons (local elections).
  • Raipur hospital reported a loss of INR 3 crores in Q1 FY27, though expected to taper.
Read the full call →

What GPT Healthcare Limited does

GPT Healthcare operates under the ILS Hospitals brand, running a network of neighborhood tertiary and quaternary-care hospitals located within dense residential catchments in Eastern India for high patient accessibility. It earns from inpatient and outpatient hospital services spanning oncology, interventional cardiology, nephrology (including renal transplants), gastroenterology, orthopaedics and robotic surgery, backed by in-house diagnostics such as MRI, CT and cardiac catheterization labs. The company also runs ancillary digital and home-care offerings, including a senior-citizen home-healthcare programme and a patient-facing mobile app. A sixth hospital, a 150-bed facility in Jamshedpur, is under construction.

Segments

  • Hospital Services
Hospitals operated
5
Total bed capacity
719 beds
Full-time consultants
115
Visiting consultants
630
Cumulative robotic surgeries performed
800+
Quality accreditations
NABH & NABL accredited
Founded 2000Headquarters Kolkata, West Bengal, IndiaEmployees 1,924 (2025-03-31) Company website

Guidance record · Q1 FY27

what the last two calls moved 18 tracked 2 delivered 2 missed 14 open
  • FY26 YoY Revenue Growth delivered said Q4 FY25 Promised: Grow at a 15% Y-o-Y growth Q1 FY27: Promise concluded in FY26. Final status was 'achieved'.
  • FY26 Consolidated EBITDA Margin missed said Q4 FY25 Promised: Expect the EBITDA margin to be 22.5% to 23% overall Q1 FY27: Promise concluded in FY26. Final status was 'missed'.
  • Total Bed Capacity delayed said Q3 FY25 Promised: 1,000 bed challenge by FY '27 / next 2 to 3 years Q1 FY27: Reiterated target of over 1,000 beds, but timeline pushed to 'next 2 years' (approx. Q1 FY29), a delay from the original 'by FY27' target.

All 18 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 17.8%, net profit up 62.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue106 102 101 107 119 +12%120 +18%126 +25%126 +18%
EBITDA23 21 21 17 23 +0%21 +0%23 +10%24 +41%
Net profit15 12 13 8 11 −27%9 −25%15 +15%13 +63%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +2.0% 1Y

₹120₹140₹160Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 11 Nov 2025Q3 FY26 — 3 Feb 2026Q4 FY26 — 19 May 2026Q1 FY27 — 4 Aug 2026

1Y: ₹156.27 on 10 Sept 2025 → ₹159.38. High ₹170.49 (31 Jul 2026), low ₹115.31 (30 Mar 2026).

How the price took the results

close before → close after

Q1 FY27
−1.1%
4 Aug
Q4 FY26
+2.9%
19 May
Q3 FY26
+0.8%
3 Feb
Q2 FY26
−0.0%
11 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 8.6% a year over 2 years, FY24 to FY26. Operating margin narrowed to 17.8%.

Year endingFY24FY25FY26
Revenue₹400 Cr₹407 Cr₹472 Cr
Operating profit₹88 Cr₹83 Cr₹84 Cr
Operating margin22.0%20.4%17.8%
Interest₹8 Cr₹4 Cr₹8 Cr
Depreciation₹17 Cr₹20 Cr₹27 Cr
Net profit₹48 Cr₹50 Cr₹43 Cr
Net margin12.0%12.3%9.1%
Cash from operations₹69 Cr₹67 Cr₹81 Cr
Free cash flow₹50 Cr₹18 Cr₹40 Cr
ROCE30.0%27.0%20.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹18 Cr₹80 Cr₹80 Cr₹82 Cr₹82 Cr₹82 Cr
Reserves₹116 Cr₹78 Cr₹85 Cr₹136 Cr₹172 Cr₹187 Cr
Borrowings₹166 Cr₹102 Cr₹82 Cr₹31 Cr₹97 Cr₹91 Cr
Other liabilities₹18 Cr₹63 Cr₹79 Cr₹96 Cr₹113 Cr₹104 Cr
Total liabilities₹317 Cr₹323 Cr₹327 Cr₹346 Cr₹463 Cr₹465 Cr
Fixed assets₹220 Cr₹220 Cr₹228 Cr₹224 Cr₹342 Cr₹342 Cr
Capital work in progress₹0 Cr₹1 Cr₹3 Cr₹6 Cr₹2 Cr₹1 Cr
Investments₹1 Cr₹10 Cr₹13 Cr₹30 Cr₹32 Cr₹43 Cr
Other assets₹97 Cr₹92 Cr₹83 Cr₹85 Cr₹87 Cr₹79 Cr
Total assets₹317 Cr₹323 Cr₹327 Cr₹346 Cr₹463 Cr₹465 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

What the price assumes

Growth trap

To justify its price of ₹159, this stock must grow earnings at 19% every year for 7 years. Our analysis caps realistic growth at ~-7%. At that growth it is worth ₹39 — downside of 75%.

Growth the price implies
19.1% a year
for 7 years, fading to 4%
It has actually compounded at
-5.4% a year
net profit, FY24–FY26 · EPS -6.9%
The gap
0.3 pp
-75% downside if it only repeats history
Price today ₹159.38 Value at the reference growth ₹39.21

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse GPT Healthcare Limited

Guides on how to read this kind of business and the numbers that matter.